West reports 4Q 2025 adjusted EPS up 12.1% to $2.04; issues 2026 guidance
West Pharmaceutical Services reported fourth-quarter 2025 net sales of $805.0 million, up 7.5%, with reported diluted EPS of $1.82, up 2.2%, and adjusted diluted EPS of $2.04, up 12.1%. The company also issued 2026 guidance calling for adjusted diluted EPS of $7.85 to $8.20, which the filing says represents growth of 7.7% to 12.5%, and assumes a mid-year 2026 close of the SmartDose 3.5mL sale to AbbVie.
Key points
- Q4 2025 net sales of $805.0 million rose 7.5%; organic growth was 3.3%, with HVP Components up 20.3%.
- Q4 2025 diluted EPS was $1.82 (up 2.2%); adjusted diluted EPS was $2.04 (up 12.1%).
- 2026 guidance: net sales of $3.215 billion to $3.275 billion and adjusted diluted EPS of $7.85 to $8.20.
- Full-year 2025 free cash flow was $468.9 million, up 69.6%; 2025 share repurchases totaled $134.0 million.
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.